Company: CMND
Filing Date: 2025-06-12
Form Type: POS AM
Source: 0001213900-25-053898
Chunk: 41

Company: Clearmind Medicine Inc.
Filing Date: 2025-06-12
Form: POS AM
Chunk 41
---
 against certain liabilities.

Item 7. Recent Sales of Unregistered Securities.

Set forth below are
the sales of all unregistered securities of ours sold by us within the past three years (i.e., since January 1, 2022, up to the date
of this registration statement) which were not registered under the Securities Act. We believe that each of such issuances was exempt
from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act, Rule 701 and/or Regulation S under the
Securities Act.

<div align='center'>II-1</div>

On February 8, 2022, we entered into a private
placement agreement with Medigus Ltd., or Medigus, pursuant to which we will raise approximately CAD$1.6 million (approximately $1.25
million). As consideration for the agreement, we agreed to issue Medigus 2,208 units, or the Medigus Units at a subscription price of
CAD$720.00 (approximately $570.00) per Medigus Unit. Each Medigus Unit is comprised of one Common Share and one warrant to purchase one
Common Share. Each warrant will be exercisable for a period of 18 months into one additional Common Share at a price per share of CAD$1,800.00.
The transaction closed in April 2022.

On January 11, 2024, we consummated a registered
direct offering of 1,468,000 common shares and 32,000 pre-funded warrants at a price of $1.60 per common share and $1.5999 per pre-funded
warrant share and a simultaneous private placement of unregistered common warrants to purchase an aggregate of up to 1,500,000 common
shares. The unregistered common warrants have an exercise price of $1.60 per share, are immediately exercisable and have a 5-year term
from the issuance date.

The privately placed
securities above were offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities
Act and Rule 506 of Regulation D promulgated thereunder since, among other things, the transactions did not involve a public offering
and the securities were acquired for investment purposes only and not with a view to or for sale in connection with any distribution
thereof.

Additionally, since January 2022, we have granted
share options and RSU’s to